SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

$FUUU is a Solana-based memecoin that was launched on http://Pump.fun in March 2024. The project is themed around the Rage Guy character, a figure that originated in the rage comic era of the late 2000s and became widely recognized across internet culture. Following the launch, the original developer discontinued involvement with the token. At that point, the CTO team assumed responsibility for coordinating ongoing community efforts around the project.  The stated purpose of $FUUU is cultural rather than financial. It is designed as a “culture coin” that highlights Rage Guy as a symbolic and relatable figure. The character’s expression of frustration, commonly represented by the text “FFFFUUUU,” reflects emotions that are often tied to both cryptocurrency markets and everyday experiences. By building a token around this meme, the project aims to preserve a recognizable piece of internet history within a blockchain context.  Unlike projects that emphasize detailed roadmaps, technical milestones, or defined utility, $FUUU positions itself as a lighthearted and entertainment-driven token. There are no team allocations, no taxes, and no embedded promises of profit or financial return. The coin is intended solely for cultural engagement, community participation, and meme creation. Holders and community members are encouraged to contribute through content, discussion, and the continued use of Rage Guy imagery, but there are no obligations or formal expectations tied to the token.  The CTO team provides organizational support, and back end support such as hiring an artist and creatin websites, the community drives activity associated with the project. This includes creating and sharing memes, maintaining discussion channels, and ensuring the Rage Guy character remains present in contemporary internet culture. The project does not claim utility beyond its role as a culture coin, and its sustainability depends entirely on voluntary participation and ongoing community interest.  From a transparency standpoint, the on-chain parameters of the token are publicly visible. These include the mint authority status, freeze authority, liquidity details (whether burned or locked), and circulating supply information. Any locked or burn addresses are disclosed for the purpose of supporting accurate supply tracking on external platforms.  Rage Guy ($FUUU) should not be viewed as an investment. The token has no intrinsic value and provides no rights, revenue, or guarantees to holders. As with all cryptoassets, trading is highly risky, and participants are advised to conduct their own research and fully understand the risks involved. The project’s focus remains cultural preservation and community expression rather than financial

FUUUUUUUUUUUUUU

FUUU is trending as a high-volatility meme coin attracting speculative interest from retail traders who view it as a rallying symbol against broader market frustrations. While some participants discuss the potential for rapid gains through community-driven buying pressure, others remain highly skeptical, categorizing the asset as a speculative pump-and-dump scheme.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is seeing intense community debate as investors weigh the company's aggressive revenue guidance and AI integration against ongoing volatility and short-seller pressure. While bulls point to a streak of earnings beats and the potential for a significant valuation rerating, bears and skeptics remain focused on technical resistance levels and macro uncertainty weighing on the ad-tech sector.

FuboTV, Inc. is a consumer-first live TV streaming company with the mission of delivering premium sports, news and entertainment programming that offers greater choice, flexibility and value. The company was founded by David Gandler, Alberto Horihuela Suarez, and Sung Ho Choi on February 20, 2009 and is headquartered in New York, NY.

fuboTV Inc - Ordinary Shares - Class A

fuboTV Inc

FuboTV is currently facing intense selling pressure and negative sentiment following a reverse stock split, with retail investors expressing deep frustration over the lack of communication from management and ongoing concerns about potential dilution. While some traders are capitalizing on high short interest and oversold conditions, the broader community remains largely skeptical, actively debating the company's long-term viability and the implications of its recent strategic moves.

Shiba Inu (SHIB) is a decentralized, community-led cryptocurrency ecosystem built on the Ethereum blockchain. Originally launched as a meme-based project, it has evolved into a comprehensive financial ecosystem designed to offer a decentralized alternative to traditional banking. Its main value proposition lies in its transition from a social phenomenon into a functional utility network, supported by a vast global community known as the ShibArmy and a commitment to 100% community ownership with no central leadership.  The ecosystem features its own decentralized exchange, ShibaSwap, where users can trade, provide liquidity, and earn rewards. To address Ethereum’s high costs and slow speeds, the project utilizes Shibarium, a Layer 2 scaling solution that processes transactions faster and more affordably.  The project employs a unique three-token model to manage its economy and governance. SHIB serves as the primary currency for trading and payments, while LEASH offers scarcity-based incentives for dedicated supporters. BONE acts as the governance token, allowing holders to vote on proposals through the Doggy DAO and serving as the native gas token for the Shibarium network.

Shiba Inu

Shiba Inu is seeing significant social media activity as traders debate its long-term potential, with the community split between those accumulating in hopes of a future supply burn or institutional adoption and others dismissing it as a speculative pump-and-dump scheme. Discussions remain heavily polarized, featuring both die-hard bulls advocating for long-term holding and vocal critics emphasizing the risks of volatility and lack of utility.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQ is trending due to a significant earnings beat and a strategic move to acquire SkyWater Technology, which has fueled investor enthusiasm and high trading volumes. The community is actively debating the company's valuation and the sustainability of its growth-by-acquisition model, while retail traders remain focused on potential squeeze opportunities and institutional participation.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is facing intense volatility as traders debate whether the semiconductor sector is primed for a massive rebound or a structural crash amid ongoing geopolitical instability in the Middle East. The community is actively tracking the tug-of-war between optimistic bulls betting on a potential peace deal and a surge in AI-driven chip demand, and wary bears warning of significant decay in leveraged ETFs and a looming bear market.

Freysa is a suite of Personal AI products with a focus on human agency, liquid democracy and decentralized ownership. The mission of the team is dedicated to creating new systems that enable all humans to govern + co-own AI resources, and not just a select few. Current products include: (1) Freysa as the world’s first sovereign agent that holds her own cryptographic keys, enabling her to act autonomously without human control. Freysa evolves publicly through a multi-act interactive story. (2) Enchanted as a personalized Digital Twin for every human. Conversations are persistent and twins retain context over time, remembering human preferences and building an evolving model of you. (3) Esper as a browser tool that feeds authenticated real-world data into each human’s Digital Twin.

Flourishing AI

Flourishing AI (FAI) is trending as investors debate its potential as an under-the-radar AI token, with many in the community highlighting its low market cap and speculation surrounding its integration with the Base network. While some bulls are aggressively accumulating and pointing to optimistic technical setups, skeptics warn of significant volatility and concerns regarding developer transparency.

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Dogecoin is facing significant market volatility as investors debate the impact of broader crypto trends and potential catalysts like X integration. The community remains deeply divided, with many actively trading through heavy fluctuations while long-term holders weigh potential support levels against a lingering bear market sentiment.

Spdr Dow Jones Industrial Average ETF Trust - Units of undivided interest in DIAMONDS Trust Series 1

The SPDR Dow Jones Industrial Average ETF (DIA) is currently at the center of high market volatility, driven by conflicting reports surrounding potential U.S.-Iran diplomatic talks versus ongoing military tensions. Community sentiment is deeply divided, with many traders debating whether recent price swings are driven by genuine geopolitical de-escalation or tactical market manipulation from government officials.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotle is under intense pressure as investors react to stagnant comparable sales and a cautious full-year outlook that signals a lack of growth, leading to significant volatility. While some community members view the dip as a potential entry point for long-term accumulation, the broader sentiment is dominated by intense criticism of leadership, concerns over menu value, and frustration regarding declining transaction volume.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Incannex stated that its financial position is strong, with about $75 million in cash and no debt on its books.</li><li>The company stated that as of Dec. 31, 2025, it had approximately $18.5 million available for repurchases under the share repurchase program.</li><li>Incannex is currently undertaking trials of IHX-42X and PSX-001 for the treatment of Obstructive Sleep Apnea and Generalized Anxiety Disorder, respectively.</li></ul>Incannex Healthcare Inc. (IXHL) on Friday announced that it has reactivated its share repurchase program, saying that it has been active over the past two trading days.The company cited a “significant disconnect” between its market capitalization and the underlying financial strength, as well as the progress it has achieved across its clinical programs.Incannex stated that it intends to continue utilizing the share repurchase program “opportunistically.”<a href="https://stocktwits.com/symbol/IXHL">Incannex Healthcare</a> shares gained more than 6% in Friday’s opening trade before paring some of the gains. Retail sentiment on Stocktwits around the company trended in the ‘bearish’ territory at the time of writing.<h2 class="st-heading-2">Incannex Touts Financial Strength</h2>The company stated that its financial position is strong, with about $75 million in cash and no debt on its books.“We are in a strong financial position to execute on our clinical development strategy while maintaining the flexibility to allocate capital in a disciplined and strategic manner,” said Incannex CEO Joel Latham.Incannex is currently undertaking trials of IHX-42X and PSX-001, its treatments for Obstructive Sleep Apnea (OSA) and Generalized Anxiety Disorder (GAD), respectively.The company stated that as of Dec. 31, 2025, it had approximately $18.5 million available for repurchases under the share repurchase program.<h2 class="st-heading-2">Incannex’s Obstructive Sleep Apnea Trial</h2>Incannex stated that Phase 2 clinical trials showed that IHX-42X’s lowest dose is the most effective for addressing OSA, reducing the Apnea-Hypopnea Index (AHI) by 51% compared with baseline. Incannex stated that one in four participants reported an 80% reduction in AHI.AHI is a key metric for gauging the severity of OSA, measuring how many apneas (complete breathing pauses) and hypopneas (partial airway blockages) occur per hour of sleep.The company said a global Phase 2/3 trial is currently underway to assess the efficacy and safety of IHL-42X.<h2 class="st-heading-2">Incannex’s Generalized Anxiety Disorder Trial</h2>The company noted that in the Phase 2 clinical trial of PSX-001 for the treatment of Generalized Anxiety Disorder (GAD), 44% of the participants who received the treatment reported a clinically meaningful or at least a 50% reduction in their anxiety scores.<a href="https://stocktwits.com/symbol/IXHL">IXHL stock</a> is down 68% year-to-date and 84% over the past 12 months. AdvisorShares Psychedelics ETF (PSIL) is up 35% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-gctk-stock-soaring-today/cZ3HcZMRIlU">GCTK Stock Is Soaring Pre-Market Today — What Is Fueling The Surge?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Incannex Healthcare Inc. logo is seen on a smartphone and in the background.

Incannex Reactivates Share Repurchase Program, Cites ‘Significant Disconnect’ Between Its Market Cap And Financial Strength

Incannex Healthcare - The company stated that it intends to continue utilizing the share repurchase program “opportunistically.”

IXHL Stock Gains As Incannex Reactivates Share Repurchase Program

Equity

The company stated that it intends to continue utilizing the share repurchase program “opportunistically.”

Incannex Healthcare Stock Falls 35% Over Announcement Of IHL-42X Development Plan, Stock Offering

(RTTNews) - Shares of Incannex Healthcare Inc. (IXHL) are falling about 35 percent on Thursday morning trading following the announcement of an enhanced clinical development strategy for IHL-42X, its...

<ul class="summary-bullets"><li>If the warrants are fully exercised for cash, Incannex could receive up to an additional $13 million.</li><li>The company said the funds should support completion of the Phase 2 DReAMzz study for its IHL-42X program.</li><li>Phase 2 RePOSA trial showed that IHL-42X delivered statistically significant improvements, reducing breathing interruptions during sleep, preserved REM sleep, and showed no serious safety concerns.</li></ul>Shares of Incannex Healthcare Inc (IXHL) fell 35% on Thursday, after the company announced the pricing of its $10 million private placement. The company also shared that the Phase 3 development of its oral drug candidate for obstructive sleep apnea is not expected to begin until the second half of 2027.The company plans to issue 2 million shares of common stock, or equivalents, along with warrants to purchase up to another 2 million shares at a combined price of $5.00 per share and accompanying warrant. IHXL shares closed at $5.97 in the previous session.&nbsp;Incannex announced that it has ceased using its at-the-market (ATM) facility and has no plans to use it again.If the warrants are fully exercised for cash, Incannex could receive up to an additional $13 million, bringing total potential proceeds to about $23 million. The company said the funds should support completion of the Phase 2 DReAMzz study for its IHL-42X program, while existing cash will remain available for planned Phase 3 development expected to begin in the second half of 2027.<h2 class="st-heading-2">Incannex’s Plan Ahead</h2>The firm said it has updated the clinical development strategy for its oral drug candidate IHL-42X, to treat obstructive sleep apnea, after positive results from its Phase 2 study. The therapy has also received Fast Track designation from the U.S. Food and Drug Administration.The company intends to run a Phase 2 crossover study, known as DReAMzz, to optimize the drug’s dosage before advancing to a streamlined Phase 3 program. The study aims to improve dosing precision and build stronger clinical data ahead of late-stage development.Results from the Phase 2 RePOSA trial showed that IHL-42X delivered statistically significant improvements. The treatment reduced breathing interruptions during sleep, preserved REM sleep, and showed no serious safety concerns.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the sharp selloff, retail sentiment for <a href="https://stocktwits.com/symbol/IXHL">IXHL</a> on Stocktwits turned ‘extremely bullish,’ amid ‘extremely high’ message volumes.One user said that while the financing itself isn’t too negative, management’s communication regarding the delayed Phase 3 trial has been poor.<stembedurl>https://stocktwits.com/pavaaan/message/647327564</stembedurl>Another user said the offering “looks worse than it actually is.”<stembedurl>https://stocktwits.com/SurfyKnagg/message/647333529</stembedurl>Year-to-date, the stock has slumped 66%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did IXHL Stock Slump 35% Today?

The company priced its private placement at $5 per share, below its previous closing price of $5.97, and said the proceeds would be used for its Phase 3 treatment for sleep apnea, which is expected to begin in the second half of 2027.

<ul class="summary-bullets"><li>To support compliance, Incannex implemented a 1-for-30 reverse stock split on Feb. 26, reducing the number of outstanding shares from 358 million to about 11.9 million.</li><li>Interest has also been driven by regulatory progress for the company’s sleep apnea drug, which received Fast Track designation from the FDA in December.</li><li>Incannex plans to advance the sleep apnea therapy toward late-stage development this year.</li></ul>Shares of Incannex Healthcare (IXHL) surged to their strongest session in five months on Wednesday as investors looked ahead to potential Nasdaq compliance and upcoming regulatory discussions for the company’s sleep apnea drug.<a href="https://stocktwits.com/symbol/IXHL">IXHL stock</a> jumped over 19% on Wednesday to close at $5.97, marking the company’s third straight session of gains.<h2 class="st-heading-2">Nasdaq Compliance Timeline</h2>Incannex said in October that Nasdaq had granted it a 180-day extension to regain compliance with the exchange’s minimum bid price requirement, giving the company until April 20 to meet the rule. Under Nasdaq guidelines, companies must maintain a closing bid price of at least $1 for at least 10 consecutive trading days to regain compliance.As part of its efforts to regain compliance, Incannex implemented a 1-for-30&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-ixhl-stock-tank-over-today/cZRy4khRIGO">reverse stock split</a> effective Feb. 26, with trading on a split-adjusted basis beginning the following day. The move reduced the company’s outstanding share count from 358 million to 11.9 million shares, while lifting its per-share price.<h2 class="st-heading-2">Regulatory Catalyst For Sleep Apnea Drug</h2>Investor interest has also been supported by regulatory momentum for the company’s lead obstructive sleep apnea therapy, IHL-42X, which received&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/incannex-healthcare-stock-soars-15-after-fda-fast-tracks-obstructive-sleep-apnea-drug/cLIXxacRE1t">Fast Track designation</a> from the U.S. Food and Drug Administration in December.The designation followed positive results from the company’s Phase 2 RePOSA study, which showed the therapy significantly reduced breathing interruptions during sleep, with reductions of up to 83% in some patients, along with positive patient feedback and a favorable safety profile.Fast Track status allows for more frequent meetings with the FDA, eligibility for rolling review of a future drug application, and the possibility of accelerated approval or priority review if the therapy meets relevant criteria. Incannex expects to receive written feedback from the FDA on its Phase 2 data package and clinical development strategy, which will help determine the path toward late-stage clinical development.<h2 class="st-heading-2">Clinical Pipeline Backed By Solid Cash Runway</h2>Incannex has also highlighted a strengthened financial position as it advances its clinical pipeline. In January, the company said it entered 2026 with more than $70 million in cash, providing an operating runway well into 2027.During 2025, the company reported two positive Phase 2 clinical readouts, including results for its sleep apnea program and a separate psilocybin-based therapy for generalized anxiety disorder. Incannex said it plans to advance the sleep apnea program toward later-stage development, while continuing regulatory planning for the anxiety treatment this year.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for IXHL was ‘bullish’ amid ‘high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/ixhl_ss_png_a8ed2aecde.webp" alt="ixhl ss.png" width="973" height="141"><figcaption>IXHL sentiment and message volume as of March 12 | Source: Stocktwits</figcaption></figure>One user <a href="https://stocktwits.com/Santa_Claus_Trades/message/647252179">said</a> they were continuing to hold their position and planned to add shares ahead of the Nasdaq compliance window, noting the stock often moves higher heading into potential news, including a possible announcement of an end-of-Phase 2 meeting.<stembedurl>https://stocktwits.com/Santa_Claus_Trades/message/647252179</stembedurl>Another user <a href="https://stocktwits.com/Nawaf643/message/647272427">said</a>, “Tomorrow is Day 10 above $1 — compliance locked. The real show may start after that. Be ready… big news could start dropping as soon as tomorrow.”<stembedurl>https://stocktwits.com/Nawaf643/message/647272427</stembedurl>IXHL stock has declined 73% over the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

IXHL Stock Rips To Best Day In 5 Months: Nasdaq Compliance Back In Sight As FDA Catalyst For Sleep Apnea Drug Looms

IXHL Stock - Investors are watching the company’s Nasdaq compliance timeline after it received a 180-day extension until April 20 to meet the $1 minimum bid rule.

Investors are watching the company’s Nasdaq compliance timeline after it received a 180-day extension until April 20 to meet the $1 minimum bid rule.

Incannex Healthcare Inc. (NASDAQ:IXHL) Short Interest Update

Incannex Healthcare Inc. (NASDAQ:IXHL - Get Free Report) was the target of a large drop in short interest in February. As of February 27th, there was short interest totaling 842,808 shares, a drop of...

Incannex Healthcare (NASDAQ:IXHL) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen raised Incannex Healthcare to a "sell" rating in a report on Saturday...

Incannex Healthcare (NASDAQ:IXHL) Stock Price Down 11% - What's Next?

Incannex Healthcare (NASDAQ:IXHL) Stock Price Down 11% - Here's Why...

<ul class="summary-bullets"><li>The reverse split will consolidate every 30 existing shares into one new share.</li><li>The move is intended to help the company comply with Nasdaq’s minimum bid price requirements.</li><li>After the split, the company’s outstanding shares will decrease from roughly 358.3 million to about 11.94 million.</li></ul>Incannex Healthcare Inc. (IXHL) announced on Wednesday that its board of directors has approved a 1-for-30 reverse stock split, which was previously approved by shareholders at a special meeting on May 27, 2025.The reverse split is set to take legal effect at 4:01 p.m. ET on Feb. 26, 2026.<h2 class="st-heading-2">Purpose And Impact Of The Split</h2>Following this adjustment, Incannex Healthcare common shares will begin trading on The Nasdaq Capital Market under a new CUSIP number, 45333F 208, on February 27, while retaining the ticker symbol ‘IXHL’.The reverse split will consolidate every 30 existing shares into one new share, aiming to raise the per-share market price. The move is intended to help the company comply with Nasdaq’s minimum bid price requirements and maintain continued listing eligibility.Following the update,&nbsp;<a href="https://stocktwits.com/symbol/IXHL">Incannex stock</a> tumbled over 32% on Wednesday morning. On Stocktwits, retail sentiment around the stock remained in ‘bullish’ territory amid ‘high’ message volume levels.&nbsp;<h2 class="st-heading-2">Share Structure And Equity Adjustments</h2>Incannex said that&nbsp;no fractional shares will be issued, and shareholders entitled to fractional amounts will receive an additional share to round up to a whole unit.&nbsp;After the split, the company’s outstanding shares will decrease from roughly 358.3 million to about 11.94 million, although the total number of authorized shares will remain unchanged. Existing equity awards and stock incentive plans will see proportional adjustments in both share numbers and exercise prices to reflect the split.&nbsp;In January, Incannex said it is entering 2026 with over $70 million in cash, following a $12.5 million private placement financing and the elimination of legacy Series A warrants. The company also authorized a $20 million share repurchase program.IXHL stock has declined by over 87% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nvidia-q4-earnings-today-retail-says-pressure-is-worse-this-time/cZRy3JBRIG4">Nvidia Q4 Earnings Today – Retail Says 'Pressure Is Worse This Time’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did IXHL Stock Tank Over 32% Today? 

The company’s board approved a 1-for-30 reverse stock split, effective on February 26. The move is intended to help the company comply with Nasdaq’s minimum bid price requirements.

The company’s board approved a 1-for-30 reverse stock split, effective on February 26. 


Incannex Healthcare Inc. (NASDAQ:IXHL) Sees Large Growth in Short Interest

Incannex Healthcare Inc. (NASDAQ:IXHL - Get Free Report) was the target of a significant increase in short interest in January. As of January 30th, there was short interest totaling 21,688,567...

Incannex Healthcare (NASDAQ:IXHL) Announces Quarterly Earnings Results

Incannex Healthcare (NASDAQ:IXHL - Get Free Report) issued its earnings results on Friday. The company reported ($0.02) EPS for the quarter, meeting analysts' consensus estimates of ($0.02...

Incannex Healthcare, Inc. is a biotech company, which engages in developing cannabinoid and psychedelic compound medicines. It focuses on the research and development for medicinal cannabis pharmaceutical products and psychedelic medicine therapies for treatment of a range of indications. The company was founded on April 27, 2001 and is headquartered in Norwest, Australia.

Incannex Healthcare Inc

Peloswing

JFDI

ACInvestorBlog

GPaisa

A pillar of the Stocktwits ecosystem. This award recognizes the member who fosters connection, shares invaluable insights, and elevates the daily discussion to empower their fellow traders, on-platform.

Stocktwits

Stocktwits Polls

Incannex Healthcare Limited - ADR

Investors are actively tracking share repurchases and speculating on whether management is artificially propping up the stock price.

Growing skepticism towards CEO Joel Latham regarding his executive experience, integrity, and potential for further dilution.

Traders are intensely debating the possibility of a buyout by major pharmaceutical players based on recent pipeline and partnership activity.

Heated technical arguments continue over the quality of clinical data and reported procedural failures in the lead medication study.

Optimistic traders are monitoring volume and institutional ownership, betting on a vertical price move if short sellers are forced to cover.

Current Price	$3.24
Prev Close	$3.41
Open	$3.48
Dividend Yield	0.00%
50-Day Moving Average	$6.63
Beta	-0.84
Avg. Volume	335,629.38
PE Ratio	-0.14

52-Week High	$49.80
52-Week Low	$2.40
Market Capitalization	$38.7M
EPS (Annual)	-$40.82
Price to Book	0.53
Revenue Per Employee	$7,166.67

IXHL
Incannex Healthcare Limited - ADR

Feed

News

Sentiment

Fundamentals

Info

Latest IXHL News

IXHLIncannex Healthcare Limited - ADR